Category Archives: Stem Cell Treatment


From Tiger Woods to Brooks Koepka, the 9 things we learned this fall on PGA Tour – Golf Channel

There was a time, not too long ago, when the fall portion of the PGA Tour schedule unfolded in a vacuum.

Few viewers. Limited interest. Little buzz.

Certain factors changed that dynamic. These days theres a clear sense of FOMO, the 11-tournament slate now representing nearly a quarter of the overall Tour calendar, and the addition of the big-money, no-cut events in Asia now offering a soft landing spot for the games elite to bank some free FedExCup points for the holidays.

The stars more frequent appearances are to our benefit, of course, and this was the best autumn the Tour has ever enjoyed.

From a record-tying win to a burgeoning rivalry to an all-time comeback, here are nine things we learned during the fall:

Itd be wrong to describe Justin Thomas' 2019 as a what-could-have-been season, considering he won once, earned more than $5 million and finished fifth in the FedExCup, but an early-season wrist injury derailed his momentum and cost him a chance to build on his majorrsum. Now 26, Thomas lone major remains the 2017 PGA, and he was a non-factor (or a no-show altogether) in the last three majors of the year. By late July hed rediscovered his world-beater form, and he blew away the field at the BMW Championship and then took it deep again at the CJ Cup.

Even in a down year he ranked fourth in strokes gained: overall. All signs point to a monster year in 2020.

That Kevin Na was able to outduel sixth-ranked Patrick Cantlay in Las Vegas was surprising enough. Then he walked off the 18thgreen and opened a vein.

Speaking in Korean for more than a minute, blinking back tears, Na attempted to address the false rumors to his fans back home. It was a puzzling rant for American viewers, but we soon learned the hidden meaning: Na was fed up with the lingering fallout from his broken engagement with a native Korean woman. Salacious details of the couples sex life had been tabloid fodder for years, and every time Na won (this was his fourth) the old stories were brought up again.

Na had stayed silent for five years, and his emotional public statement overshadowed what was a hard-fought victory.

With this compelling backdrop hes even more interesting than we already thought.

Less than one week after sending an emotional message back home to South Korea, Kevin Na is breaking the silence hes kept through years ofpersonal anguish.

Any discussion of the games young guns typically leaves out one of the youngest: Joaquin Niemann, who only turned 21 earlier this month. The Chilean didnt go to college, and so he didnt receive the same sort of splashy introduction as Matthew Wolff (20), Collin Morikawa (22) and Viktor Hovland (22).

Though he earned his Tour card without going through Q-School, Niemann fully announced his arrival with a resounding win in the season-opening Greenbrier. Hell soon star on another big stage, as a captains pick for the upcoming Presidents Cup.

The No. 1 player in the world is on the DL. This fall Brooks Koepka revealed that his knee had bothered him for months and required stem-cell treatment after the Tour Championship. Upon his return he said that he was happy to finally play pain-free, then he slipped on wet concrete in Korea and reinjured it.

Details on Koepkas injury have been sparse, but its troublesome enough that he withdrew from the Presidents Cup. His return date to the PGA Tour is unclear, but it doesnt figure to be a long-term issue hes signed up for another trip to Saudi Arabia in the middle of January.

With the extra time to heal, Koepka should come back firing in 2020.

Its possible that the build-up will be more interesting than the actual competition, which over the past two decades has been laughably one-sided. There was the will-he-or-wont-he? drama surrounding Tiger Woods playing-captain decision. There was Woods granting former pariah Patrick Reed a one-year reprieve. And then there was the uncertainty regarding the health of the No. 1 player in the world, with Koepka bowing out and Woods tapping a rusty Rickie Fowler with his extra captains pick.

Worldwide travel, a unique venue and the risk of embarrassment should keep this Presidents Cup close. But if its another American rout, at least the run-up to Royal Melbourne has been highly entertaining.

While some questioned Tiger Woods' decision to add Rickie Fowler to the U.S. Presidents Cup team, those who know Woods best aren't surprised.

Instead of withdrawing from the Safeway Open to spend more time with his ailing grandfather, Cameron Champ instead decided to honor him by playing and then winning.

Mack Champ had endured racial discrimination while growing up in Texas, but he was the man responsible for molding the game of one of the Tours uber-talented prospects.

Champ won in the fall of 2018 but tweaked his back and failed to live up to lofty expectations. Macks stomach-cancer diagnosis hit the family hard, and all Cameron needed to get back on track was a little inspiration.

In the teary aftermath of his victory in Napa, he said, This will be the greatest moment in my golf career.

The greatest, maybe not, but itll certainly be the most meaningful. Mack Champ died less than a month later.

Cameron Champ won the Safeway Open on Sunday, and he then celebrated through tears with his dad and grandpa (via phone).

It was a typical Brooks Koepka answer: Honest, blunt, with a dose of dismissiveness. When asked about the storyline that Rory McIlroy is threatening his throne, setting the stage for an epic duel in 2020, Koepka scoffed: Ive been out here for, what, five years? Rory hasnt won a major since Ive been on the PGA Tour. So I dont view it as a rivalry.

What Koepka said, of course, is true. And McIlroy didnt disagree, even if he said he didnt need to be reminded of his major shortcomings. Though McIlroy didnt fire back publicly, its reasonable to think that Brooks barb got under his skin. How could it not?

Letting his clubs do the talking, McIlroy finished the year strong: a third at the Zozo, a win at the WGC in China and then a fourth-place showing in Dubai, narrowing the gap at the top of the world rankings.

Koepka might not view this as the beginning of a rivalry with McIlroy, but his icy dismissal likely just created one.

World No. 1 Brooks Koepka downplayed the notion that there is any sort of rivalry between him and reigning FedExCup champ Rory McIlroy.

A year agoone-time Tour winner Brendon Toddconsidered opening a pizza franchise thats how dire things had gotten. The full-swing yips had torpedoed his confidence and left him without a permanent place to play, but his work with swing coach Bradley Hughes and mental coach Ward Jarvis kept him invested in the process.

Results were steady but unspectacular, at least until this fall, when he ripped off a win in Bermuda, backed it up in Mexico and then was 18 holes from notching three wins in four weeks.

Everyone loves a comeback story, but Todds is one of the most improbable in recent memory. He ended last year at No. 2,006 in the world. He now sits at 72nd.

Tiger Woods resounding Masters victory had us making bold predictions for the future 83! 19! and then he looked hobbled the rest of the season. It wasnt until this fall that we learned why hed fallen off: He underwent arthroscopic knee surgery to fix an issue that apparently had bothered him for a year.

When he showed up in Japan for the inaugural Zozo Championship, the conventional wisdom held that Woods would be rusty but needed a good performance to warrant a pick for the Presidents Cup. Then he looked nearly flawless in beating an elite, limited field to win for the 82ndtime on Tour, matching Sam Sneads all-time record.

Woods swing looks as pure as ever, but how hell play in 2020 is anyones guess. How will his soon-to-be 44-year-old body hold up to the stress of another full season? Will he add a few events to try and qualify for his last Olympics? Can he move even closer to Jack?

As always with Woods, itll be fascinating to watch.

See the original post here:
From Tiger Woods to Brooks Koepka, the 9 things we learned this fall on PGA Tour - Golf Channel

Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Future Growth, Industry Verticals, and Research Forecast upto 2026 – The Denton Chronicle

The global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market is fueled by various factors, according to a detailed assessment explained in the report. This study shows how important in-depth analysis should be, and how it greatly affects the quality of information provided to the readers. The market for Platelet Rich Plasma and Stem Cell Alopecia Treatment Market extensively covers various highlights in the report that includes competitive vista, growth propelling factors, regional outreach, targeted consumers, major obstacles, and others.

Get Free Sample PDF for Professional Insights:https://www.researchmoz.us/enquiry.php?type=S&repid=2227069

Global Platelet Rich Plasma & Stem Cell Alopecia Treatment Market: Overview

This report analyzes the current and future scenario of the global platelet rich plasma & stem cell alopecia treatment market for the period 2018 to 2026. Rise in awareness about platelet rich plasma therapies and stem cell therapies, increase in funding for alopecia treatment research and stem cell research, and increase in the incidence of autoimmune hair loss disorders are likely to be major drivers of the global platelet rich plasma & stem cell alopecia treatment market during the forecast period.

The global platelet rich plasma & stem cell alopecia treatment market report comprises an elaborate executive summary, including a snapshot that provides information on various segments of the market. It also provides information and data analysis of the global market with respect to segments based on treatment, indication, end-user, and region. A detailed qualitative analysis of drivers, restraints, and opportunities of the market has been provided in the market overview section. Additionally, the section comprises a competitive matrix and profiles of key market players, along with business overview, to project the competitive landscape of the market. The section also provides presence of key players working in the development of stem cell and platelet rich pharmaceutical products, thereby presenting a thorough analysis of the overall competitive scenario in the global platelet rich plasma & stem cell alopecia treatment market.

Global Platelet Rich Plasma & Stem Cell Alopecia Treatment Market: Key Segments

Based on treatment, the global platelet rich plasma & stem cell alopecia treatment market has been segmented into platelet rich plasma therapy and stem cell therapy. The stem cell therapy segment has been further classified into bone marrow treatment and adipose treatment. In terms of indication, the global platelet rich plasma & stem cell alopecia treatment market has been classified into androgenic alopecia, congenital alopecia, cicatricial or scarring alopecia and others. Based on end-user, the global platelet rich plasma & stem cell alopecia treatment market has been divided into hospitals, dermatology clinics, and others. The market size and forecast for each of these segments have been provided for the period 2018 to 2026, along with their respective CAGR for the forecast period 2016 to 2026, considering 2017 as the base year.

Global Platelet Rich Plasma & Stem Cell Alopecia Treatment Market: Regional Outlook

In terms of region, the global platelet rich plasma & stem cell alopecia treatment market has been segmented into five major regions: North America (the U.S. and Canada), Europe (the U.K., Germany, France, Spain, Italy, and Rest of Europe), Asia Pacific (India, China, Japan, Australia & New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East & Africa (South Africa, GCC Countries, and Rest of Middle East & Africa). The market size and forecast for each of these regions and the mentioned countries have been provided for the period 2018 to 2026, along with their respective CAGR for the forecast period 2016 to 2026, considering 2017 as the base year. The research study also covers the competitive scenario in these regions.

Get Assistance on this report at:https://www.researchmoz.us/enquiry.php?type=E&repid=2227069

( *Fill the form and our sales representative will get back to you for assistance )

Companies Mentioned in the Report

The report also profiles major players operating in the global platelet rich plasma & stem cell alopecia treatment market based on various attributes, such as company overview, financial overview, pipeline portfolio, product portfolio, business strategies, and recent developments. The players covered in the report include Kerastem, Eclipse, Regen Lab SA, Stemcell Technologies, Inc., RepliCel Life Sciences, Histogen, Inc., and Glofinn Oy.

The global platelet rich plasma & stem cell alopecia treatment market has been segmented as below:

Market Segment by Regions, regional analysis covers

Scope of the Market: This report focuses on the global market, especially in North America, Europe, Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, types and applications.

Research objectives: To study and estimate the market size of Platelet Rich Plasma and Stem Cell Alopecia Treatment Market, in terms of value. To find growth and challenges for the global market. To study worthwhile expansions such as expansions, new services launches in Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market. To conduct the pricing analysis for the global market. To classify and assess the side view of important companies of Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market.

Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Report gives answers to Following Vital Questions:1. What are the risks associated with the sourcing of raw material, or holding the line on costs of services?2. Who are the emerging competitors in the Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market?3. Expected percentage of the Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Growth over the upcoming period?4. Why does Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market have high growth potential?5. How does this report match with Investment Policy Statement?

For More Information Kindly Contact:

ResearchMozMr. Nachiket Ghumare,90 State Street,Albany NY,United States 12207Tel: +1-518-621-2074USA-Canada Toll Free: 866-997-4948Email: [emailprotected] Media Release: https://www.researchmoz.us/pressrelease

Follow us on Blogger @ https://buzzpocket.blogspot.com/

Read more from the original source:
Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Future Growth, Industry Verticals, and Research Forecast upto 2026 - The Denton Chronicle

Stem Cell Therapy Market Gain Impetus due to the Growing Demand over 2025 – Guru Online News

Stem cells are most vital cells found in both humans and non-human animals. Stem cells are also known as centerpiece of regenerative medicine. Regenerative medicines have capability to grow new cells and replace damaged and dead cells. Stem cell is the precursors of all cells in the human body. It has the ability to replicate itself and repair and replace other damaged tissues in the human body. In addition, stem cell based therapies are used in the treatment of several chronic diseases such as cancer and blood disorders.

The globalstem cell therapy marketis categorized based on various modes of treatment and by therapeutic applications. The treatment segment is further sub-segmented into autologous stem cell therapy and allogeneic stem cell therapy. The application segment includes metabolic diseases, eye diseases, immune system diseases, musculoskeletal disorders, central nervous system disorders, cardiovascular diseases and wounds and injuries.

Get Enquiry More About This Report:http://www.marketgrowthanalysis.com/reports/sample/217

Stem Cell Therapy Market, By Treatments:

Allogeneic Stem Cell TherapyAutologous Stem Cell Therapy

Stem Cell Therapy Market, By End Users:

HospitalsAmbulatory Surgical Centers

Stem Cell Therapy Market, By Application:

OncologyCentral Nervous System DiseasesEye DiseasesMusculoskeletal DiseasesWound & InjuriesMetabolic DisordersCardiovascular DisordersImmune System Disorders

Stem Cell Therapy Market, By Geography:

North AmericaEuropeAsia PacificMiddle East & AfricaLatin America

Get Request For Discount:http://www.marketgrowthanalysis.com/reports/enquiry/217

In terms of geographic, North America dominates the global stem cell therapy market due to increased research activities on stem cells. The U.S. represents the largest market for stem cell therapy followed by Canada in North America. However, Asia is expected to show high growth rates in the next five years in global stem cell therapy market due to increasing population. In addition, increasing government support by providing funds is also supporting in growth of the stem cell therapy market in Asia. China and India are expected to be the fastest growing stem cell therapy markets in Asia.

Key Players in the Stem Cell Therapy Market are:

Chiesi Farmaceutici S.P.A Are:Gamida CellReNeuron Group, plcOsiris Therapeutics, Inc.Stem Cells, Inc.Vericel Corporation.Mesoblast, Ltd.

Full View of Report Analysis:http://www.marketgrowthanalysis.com/stem-cell-therapy-market

Continue reading here:
Stem Cell Therapy Market Gain Impetus due to the Growing Demand over 2025 - Guru Online News

Stem Cell Therapy Market Size, by Therapeutic Application (Musculoskeletal Disorders, Wounds and Injuries), by Cell Source (Adipose Tissue-derived…

Stem Cell Therapy MarketGlobal Industry Report provides a detailed analysis of the market historical data, facts, regional sales, industry share, growth factors, top manufacturers overview and forecast to 2026. Stem Cell Therapy market research study presents brief information about definitions, products market features, competitive landscape, market segmentation, business opportunity and expert opinions.

Get Sample Copy athttps://www.orianresearch.com/request-sample/1348964

The report firstly introduced the Stem Cell Therapy basics: definitions, classifications, applications and market overview; product specifications; manufacturing processes; cost structures, raw materials and so on. Then it analysed the worlds main region market conditions, including the product price, profit, capacity, production, supply, demand and market growth rate and forecast etc. In the end, the report introduced new project SWOT analysis, investment feasibility analysis, and investment return analysis.

With tables and figures helping analyse worldwide Stem Cell Therapy market, this research provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market. .

No. of Pages: 121

For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Inquire more or share questions if any before the purchase on this report @https://www.orianresearch.com/enquiry-before-buying/1348964

The information for each competitor includes:

Market Share In the context of China-US trade war and global economic volatility and uncertainty, it will have a big influence on this market. Stem Cell Therapy Report by Material, and Geography Global Forecast to 2026 is a professional and comprehensive research report on the worlds major regional market conditions, focusing on the main regions (North America, Europe and Asia-Pacific) and the main countries (United States, Germany, United Kingdom, Japan, South Korea and China).

Order a copy of Report @https://www.orianresearch.com/checkout/1348964

Key Points Table of Contents

Chapter 1 Stem Cell Therapy Industry Overview

Chapter 2 Stem Cell Therapy Up and Down Stream Industry Analysis

Chapter 3 Asia Stem Cell Therapy Market Analysis

Chapter 4 2014-2019 Asia Stem Cell Therapy Productions Supply Sales Demand Market Status and Forecast

Chapter 5 Asia Stem Cell Therapy Key Manufacturers Analysis

Chapter 6 Asia Stem Cell Therapy Industry Development Trend

Chapter 7 North American Stem Cell Therapy Market Analysis

Chapter 8 2014-2019 North American Stem Cell Therapy Productions Supply Sales Demand Market Status and Forecast

Chapter 9 North American Stem Cell Therapy Key Manufacturers Analysis

Chapter 10 North American Stem Cell Therapy Industry Development Trend

Chapter 11 Europe Stem Cell Therapy Market Analysis

Chapter 12 2014-2019 Europe Stem Cell Therapy Productions Supply Sales Demand Market Status and Forecast

Chapter 13 Europe Stem Cell Therapy Key Manufacturers Analysis

Chapter 14 Europe Stem Cell Therapy Industry Development Trend

Chapter 15 Stem Cell Therapy Marketing Channels Development Proposals Analysis

Chapter 16 Development Environmental Analysis

Chapter 17 Stem Cell Therapy New Project Investment Feasibility Analysis

Chapter 18 2014-2019 Global Stem Cell Therapy Productions Supply Sales Demand Market Status and Forecast

Chapter 19 Global Stem Cell Therapy Industry Development Trend

Chapter 20 Global Stem Cell Therapy Industry Research Conclusions

About Us

Orian Research is one of the most comprehensive collections of market intelligence reports on The World Wide Web. Our reports repository boasts of over 500000+ industry and country research reports from over 100 top publishers. We continuously update our repository so as to provide our clients easy access to the worlds most complete and current database of expert insights on global industries, companies, and products. We also specialize in custom research in situations where our syndicate research offerings do not meet the specific requirements of our esteemed clients.

Contact Us

Ruwin Mendez

Vice President Global Sales & Partner Relations

Orian Research Consultants

US: +1 (415) 830-3727 | UK: +44 020 8144-71-27

Email:[emailprotected]

See the original post:
Stem Cell Therapy Market Size, by Therapeutic Application (Musculoskeletal Disorders, Wounds and Injuries), by Cell Source (Adipose Tissue-derived...

Global Musculoskeletal Disorder Stem Cell Therapy Market 2019 by Manufacturers, Countries, Type and Application, Forecast to 2025 – Avon Lake Ledger

The market research report of the global "Musculoskeletal Disorder Stem Cell Therapy Market" is a fundamental study carried out by experts with a perspective of the global market. It gets to the details of competing for the structure of industries worldwide. Composed by using proficient standardized tools like S.W.O.T Analysis, the global Musculoskeletal Disorder Stem Cell Therapy market research report provides a thorough judgment of the global Musculoskeletal Disorder Stem Cell Therapy market.

The global Musculoskeletal Disorder Stem Cell Therapy market research report provides a complete estimation of CAGR of the concerned period in percentages which will guide the users to take choice-based decisions over the predicted chart. The major players [Osiris Therapeutics, NuVasive, Takeda (TiGenix), Medi-post] who are leading the Musculoskeletal Disorder Stem Cell Therapy market throughout the globe are also covered in the report.

Ask for sample link here: http://www.marketresearchstore.com/report/global-musculoskeletal-disorder-stem-cell-therapy-market-2019-497936#RequestSample

The experts have calculated the size of the global Musculoskeletal Disorder Stem Cell Therapy market on the basis of 2 major aspects: 1) Income (US Dollars) and 2) Production Volume. The subtle analysis of the key chunks of the Musculoskeletal Disorder Stem Cell Therapy market and their geographical diversification [Allogeneic, Autologous] all the world has also been carried out. Numerous properties of the global Musculoskeletal Disorder Stem Cell Therapy market like upcoming aspects, limitations, and growth factors related to every segment [Muscle disease, Skeletal disease] of the report have been put up thoroughly.

The global Musculoskeletal Disorder Stem Cell Therapy market research report covers up each and every characteristic of the global Musculoskeletal Disorder Stem Cell Therapy market right from the basic fundamental info of the market to that of various important criteria based on which the global Musculoskeletal Disorder Stem Cell Therapy market has been diversified.

The global Musculoskeletal Disorder Stem Cell Therapy market research report covers an in-depth analysis of current policies, rules, and regulations along with the chain of global Industries. Other than this, factors like production chain, key producers, goods, supply as well as demand for those goods along with the price structure as well as the revenue are also covered in the global Musculoskeletal Disorder Stem Cell Therapy market research report.

Inquire about the report here: http://www.marketresearchstore.com/report/global-musculoskeletal-disorder-stem-cell-therapy-market-2019-497936#InquiryForBuying

The various properties of supply and demand, chronological presentation, manufacturing capacity along with the detailed analysis of the global Musculoskeletal Disorder Stem Cell Therapy market are also calculated in the global Musculoskeletal Disorder Stem Cell Therapy market research report.

Set of Chapters:

1. Musculoskeletal Disorder Stem Cell Therapy Market outline

2. International Musculoskeletal Disorder Stem Cell Therapy market Followed by makers

3. world Musculoskeletal Disorder Stem Cell Therapy Market capability, Generation, Sales (Worth ) by Region (2019-2028)

4. world Musculoskeletal Disorder Stem Cell Therapy Market provide (Production), Presence, Export, printed by Region (2019-2028)

5. International Musculoskeletal Disorder Stem Cell Therapy market Production, Revenue (Worth ), value Trend by kind

6. International Musculoskeletal Disorder Stem Cell Therapy marketing research by Application

7. Musculoskeletal Disorder Stem Cell Therapy Market makers Profiles/Analysis

8. Musculoskeletal Disorder Stem Cell Therapy Market producing analysis

9. Industrial Chain, Best Sourcing Strategy and Down-stream consumers

10. Marketing-strategy Analysis, Distributors/Traders

11. Market result sides designation

12. World Wide Musculoskeletal Disorder Stem Cell Therapy Market Forecast (2019-2028)

13. Musculoskeletal Disorder Stem Cell Therapy research Findings and call

14. Appendix

Research Objective :

Our panel of trade contributors moreover as trade analysts across the worth chain have taken vast efforts in doing this group action and heavy-lifting add order to produce the key players with useful primary & secondary data concerning the world Musculoskeletal Disorder Stem Cell Therapy market. additionally, the report additionally contains inputs from our trade consultants that may facilitate the key players in saving their time from the interior analysis half. firms WHO get and use this report are going to be completely profited with the inferences delivered in it. Besides this, the report additionally provides an in-depth analysis of Musculoskeletal Disorder Stem Cell Therapy sales moreover because of the factors that influence the shoppers moreover as enterprises towards this method.

Thanks for reading this article; you'll be able to additionally get individual chapter wise section or region wise report versions like North America, Europe, Asia-Pacific, South America, geographic area and continent."

Sorry! The Author has not filled his profile.

Continued here:
Global Musculoskeletal Disorder Stem Cell Therapy Market 2019 by Manufacturers, Countries, Type and Application, Forecast to 2025 - Avon Lake Ledger

Translink in Armagh holding stem cell registration event in memory of Gavin McNaney – Armagh i

Gavin McNaney, who passed away two years ago.

Translink are hosting a blood stem cell registration event and coffee morning this Saturday as part of the Somebodys Stranger campaign, in memory of Armagh man Gavin McNaney, who passed away two years ago.

It will take place from 10am until 2pm and it is a painless process which could potentially save a life.

Former St Catherines College teacher Gavin was just 37 years of age when he passed on November 18, 2017.

He had been diagnosed with Acute Lymphoblastic Leukaemia whilst teaching in Dubai.

Gavin spent months in hospital undergoing treatment and had a bone marrow transplant in London.

But after contracting a common cold and an infection to his lungs, his life was sadly cut short and he passed away peacefully with mum and dad, Nuala and Pat, by his side.

Friend Karl McQuaid has been raising funds and awareness after the passing of his life-long friend, whom he had first met when they both attended St Patricks Grammar School in Armagh.

He has been running registration events as part of his Somebodys Stranger campaign for nine months in Gavins memory and is keen to advise people just how easy it is to register .

He who would like to thank Leanne Armstrong and her colleagues at Translink for inviting them to come along told Armagh I : Joining the stem cell register is quick, easy and pain-free.

Potential donors have a swab taken of the inside of their cheeks with the whole process taking just a few minutes. They will then be added to DKMSs worldwide database and could be contacted at any time should they be a genetic match for a blood cancer sufferer anywhere in the world.

Those lucky enough to be a match would then be asked to donate their stem cells in a pain-free procedure similar to giving blood. This could save the life of the cancer sufferer.

Donations are at your own discretion at the event with all proceeds going to Leukaemia & Lymphoma NI Northern Irelands only charity dedicated to fighting blood cancers.

Those willing to join the register should be in general good health and aged between 18 and 55.

All are urged to come along on Saturday morning, when the city will be full of revellers for the annual Georgian Day event. Please take time to come along to the bus station and help make a huge difference.

See more here:
Translink in Armagh holding stem cell registration event in memory of Gavin McNaney - Armagh i

Induction Therapy and Hematopoietic Stem Cell Transplantation for Mixed-Phenotype Acute Leukemia – Hematology Advisor

Home Topics Leukemia

A recent analysis of treatment options for patients with mixed-phenotype acute leukemia (MPAL) suggests favorable outcomes may be obtained with frontline therapy using a chemotherapy regimen usually administered to patients with acute lymphoblastic leukemia (ALL) and without hematopoietic stem cell transplantation (HSCT). Results of this analysis were published in Cancer.

In this central review of MPAL outcomes, the Childrens Oncology Group Acute Leukemia of Ambiguous Lineage Task Force studied a cohort of 54 patients aged 1 to 30 years with diagnoses of MPAL who were enrolled in clinical trials involving ALL or acute myeloid leukemia (AML) treatments.

Induction therapies typically consisted of ALL treatment regimens, AML treatment regimens, or a hybrid of both approaches. A variety of postinduction treatment options, with or without HSCT, were also included.

Patients with MPAL who were given ALL (72%) or AML (24%) induction treatments did not significantly differ from each other in reported baseline characteristics.

End-of-induction complete remission was achieved by 72% of patients treated with an ALL induction regimen and by 69% of patient given an AML induction regimen.

Among all patients in the cohort, the 5-year overall survival rate was 77%; among patients who received ALL chemotherapy without HSCT, the 5-year overall survival rate was 84%. The 5-year event-free survival rate was 72% for the total cohort and 75% among those who received ALL chemotherapy without HSCT.

The researchers stated that their findings demonstrated that durable remissions are possible for a subset of patients with MPAL receiving ALL chemotherapy without HSCT consolidation. They also described a forthcoming prospective clinical trial that will test a minimum residual disease-guided treatment approach with ALL therapy and without HSCT in patients with MPAL.

Reference

Please login or register first to view this content.

LoginRegister

Next post in LeukemiaClose

Read the original:
Induction Therapy and Hematopoietic Stem Cell Transplantation for Mixed-Phenotype Acute Leukemia - Hematology Advisor

Tendon stem cell discovery could lead to improvements in injury recovery – Drug Target Review

Researchers have discovered the existence of tendon stem cells, which could lead to improvements in treating tendon injuries, avoiding surgery.

New research has revealed the existence of tendon stem cells which could potentially be harnessed to improve tendon recovery after an injury and perhaps even avoid surgery.

The research was led by Chen-Ming Fan at the Carnegie Institution of Science, US.

Once tendons are injured, they rarely fully recover, which can result in limited mobility and require long-term pain management or even surgery. This is due to fibrous scars, which disrupt the tissue structure of the tendon.

This image shows the Patellar tendon 30 days after an injury. The red marks newly discovered tendon stem cells that have self-renewed and are layered over green marked, original tendon cells. During regeneration, some tendon stem cells differentiate to make newly regenerated tendon cells a process during which they transition into a yellow-orange colour. The blue indicates cellular nuclei (credit: Tyler Harvey).

Fan, along with Carnegies Tyler Harvey and Sara Flamenco, revealed all of the cell types present in the Patellar tendon, found below the kneecap, including previously undefined tendon stem cells.

Because tendon injuries rarely heal completely, it was thought that tendon stem cells might not exist, said lead author Harvey. Many searched for them to no avail, but our work defined them for the first time.

The teams research showed that both fibrous scar tissue cells and tendon stem cells originate in the same space the protective cells that surround a tendon. Moreover, these tendon stem cells are part of a competitive system with precursors of fibrous scars, which explains why tendon healing is such a challenge.

It was thought that tendon stem cells might not exist but our work defined them for the first time

The team demonstrated that both tendon stem cells and scar tissue precursor cells are stimulated into action by a protein called platelet-derived growth factor-A. When tendon stem cells are altered so that they do not respond to this growth factor, then only scar tissue and no new tendon cells form after an injury.

Tendon stem cells exist, but they must outcompete the scar tissue precursors in order to prevent the formation of difficult, fibrous scars, Fan explained. Finding a therapeutic way to block the scar-forming cells and enhance the tendon stem cells could be a game-changer when it comes to treating tendon injuries.

The research was published in Nature Cell Biology.

See the rest here:
Tendon stem cell discovery could lead to improvements in injury recovery - Drug Target Review

2 Small-Cap Biotechs That Soared Last Week – Motley Fool

The stocks of Magenta Therapeutics (NASDAQ:MGTA) and Molecular Templates (NASDAQ:MTEM) bolted skywards last week, to the tune of 39% and 28% respectively.

Cutting-edge gene-editing therapies, chimeric antigen receptor T-cell (CAR-T) treatments, and stem cell transplants all require priming or conditioning regimens. Doctors today utilize older chemotherapy drugs or radiation, which often lead to infection or hospitalization. Magenta Therapeutics and Molecular Templates are among the companies seeking to develop less toxic, non-chemotherapy options for patients.

Image source: Getty Images.

On Nov. 18, Molecular Templates and Vertex Pharmaceuticals (NASDAQ:VRTX) forged a discovery and development collaboration to create novel targeted conditioning regimens applicable to gene-editing, CAR-T, and stem cell transplants. Vertex shelled out $38 million of up-front cash and an equity investment in Molecular Templates. The stock barely flinched, losing $0.03 from the prior day's closing price.

The next day, Nov. 19, Vertex and its collaborator CRISPR Therapeutics announced positive safety and efficacy data for the gene-editing therapy CTX001 in its first two patients. One patient had severe sickle cell disease; the other had beta thalassemia. These interventions edit a patient's genome, potentially allowing for a one-time curative treatment. Both patients received the chemotherapy busulfan prior to CTX001.

Revisiting the prior day's collaboration announcement, biotech investors focused on comments made by Vertex about how Molecular Templates could benefit the CTX001 program.

Vertex's Chief Scientific Officer David Altshuler said,

"We believe that gene editing holds significant promise in the treatment of severe hemoglobinopathies such as sickle cell disease and beta thalassemia, and Molecular Templates' unique technology platform could play an important role in creating a targeted conditioning regimen that could replace chemotherapy currently required in conditioning regimens and thus enhance the overall future treatment experience for patients."

Investors jumped on the message from Vertex, one of the biotech industry's stalwarts: Non-chemotherapy conditioning approaches are the future for gene and cell therapies.

In response, the stocks of other companies focused on achieving that goal (like Magenta) shot up. In fact, Magenta's nearly 40% gain in share price came during a week when it didn't release any news.

Magenta plans to present data on Dec. 6 at the American Society of Hematology's Annual Meeting for its lead program CD117-ADC. Targeting a protein on hematopoietic stem cells called CD117, the treatment eliminated mutated cells without the need for chemotherapy or radiation. Magenta believes CD117-ADC can potentially be used for genetic diseases like sickle cell disease, prior to either gene therapy or hematopoietic stem cell transplantation (HSCT).

Magenta and Molecular Templates are not the only players in the field. Forty Seven and bluebird bio paired up earlier this month to develop antibody-based conditioning regimens for HSCT. According to the World Health Organization, 50,000 HSCT procedures are performed annually worldwide.

Furthermore, recently approved CAR-T for cancer, such as Kymriah from Novartis or Yescarta from Gilead Sciences, require three days of cyclophosphamide and fludarabine. Developers of these and next-generation CAR-T treatments also seek to eliminate chemotherapy or radiation.

Patients greatly need less toxic methods to prepare them for gene- and cell-based therapies, or stem cell and bone marrow transplants. Many patients, particularly the elderly, are deemed ineligible for these interventions because the toxicity could be too severe. Any success could have broad implications for the treatment of cancers and genetic diseases.

While a variety of successful approaches may ultimately emerge, Magenta has taken an early lead with CD117-ADC. Molecular Templates, with Vertex as a seasoned partner by its side, may soon leap onto the scene with a targeted approach derived from its "engineered toxin bodies" platform.

The investor takeaway is clear: New treatment modalities will be dependent on non-chemotherapy conditioning. Investors in biotech companies that can figure out that piece of the puzzle should be richly rewarded.

Visit link:
2 Small-Cap Biotechs That Soared Last Week - Motley Fool

Cell Culture Market Size to Exceed US $42 Billion by 2026 – Post Register

SELBYVILLE, Del. - November 25, 2019 - ( Newswire.com )

As per the latest research report titled " Cell Culture Market Share, Size, Trends & Industry Analysis Report By Consumables (Media, Sera, Reagents); By Product (Pipetting Instruments, Centrifuges, Biosafety Instruments, Culture Systems, Incubators, Cryostorage Equipment); By Application and By Regions: Segment Forecast, 2019 2026"available with Market Study Report LLC, the global cell culture market is anticipated to grow with a CAGR of 11.8% through the year 2026.

Cell culture is effectively applied in evaluation and treatment of diseases such as cancer and Alzheimers. Increasing adoption of techniques to develop high-quality plant actives, coupled with rising focus of key players towards widening their cell reservoir and recruiting trained experts for enhanced efficiency are propelling the growth of the cell culture market.

Request Sample Copy of This Report @ https://www.marketstudyreport.com/request-a-sample/1868580/

Moreover, increasing demand for cell culture is unable to be met by conventional development and manual handling, which is compelling the incorporation of automated techniques that offer higher purity and larger quantity. Constant advancements in techniques, along with discovery of new functions of cell cultures will further augment the expansion of the cell culture market.

Based on product type, the cell culture market is classified into pipetting instruments, biosafety instruments, incubators, centrifuges, culture systems, and cryostorage equipment. As per application spectrum, the industry is divided into tissue culture & engineering, drug development, vaccine production, biopharmaceuticals, gene therapy, and toxicity testing.

In terms of consumables, the cell culture market is categorized as media, reagents, and sera. The report cites that thesera segment held 45% revenue share of the cell culture market in 2018, owing to surging commercialization of the segment and the high price of the product.

Considering the regional landscape, the Asia Pacific cell culture market is presumed to gain lucrative growth opportunities over the forecast period, on account of surging need for advancements and manufacturing of medications, vaccinations, and biologics. Supportive federal reforms, inflow of funding from market players, and untouched potential of market will further drive the regional market growth.

Main contenders of the global cell culture market profiled in the report are Sartorius, Thermo Fisher Scientific, Sigma-Aldrich Co., General Electric, Eppendorf, Merck, Becton, Promocell, Lonza, and Dickinson & Company.

Request Discount on This Report @ https://www.marketstudyreport.com/check-for-discount/1868580/

Question & Answer: Cell Culture Market

Question 1: Why is the cell culture market registering constant growth?

Answer: Cell culture is effectively applied in evaluation and treatment of diseases such as cancer and Alzheimers. Increasing adoption of techniques to develop high-quality plant actives, coupled with rising focus of key players towards widening their cell reservoir and recruiting trained experts for enhanced efficiency are propelling growth of the cell culture market.

Question 2: Which segment held a significant share of the cell culture market in 2018?

Answer: In terms of consumables, cell culture market is categorized as media, reagents, and sera. The report cites that thesera segment held 45% revenue share of the cell culture market in 2018, owing to surging commercialization of the segment and the high price of the product.

Question 3: How is the Asia Pacific region impacting the growth of cell culture market?

Answer: Asia Pacific cell culture market is presumed to gain lucrative growth opportunities over the forecast period, on account of the surging need for advancements and manufacturing of medications, vaccinations, and biologics. Supportive federal reforms, inflow of funding from market players, and untouched potential of the market will further drive the regional market growth.

Question 4: What companies define the competitive landscape of cell culture market?

Answer: Main contenders of the global cell culture market profiled in the report are Sartorius, Thermo Fisher Scientific, Sigma-Aldrich Co., General Electric, Eppendorf, Merck, Becton, Promocell, Lonza, and Dickinson & Company.

Related Report:

Stem Cell Therapy Market Size By Type, By Application, End-users Forecast, 2019 - 2025

Stem Cell Therapy Market will exceed USD 15 billion by 2025, as per a new research report.

Increasing research on developing novel therapies and personalized medicines will foster stem cell therapy market growth. For instance, scientists are extensively researching methods to regenerate healthy heart cells from placenta that can be used in patients after myocardial infarction. This discovery will help to cure patients suffering from cardiovascular diseases and reduce mortality rates. Researchers are further examining different aspects of stem cell therapy for its applications in neurological disorders. Thus, increasing R&D activities to promote developments in stem cell therapy will positively impact industry growth.

A rising geriatric population will positively influence the industry growth in coming years. Elderly people are susceptible to degenerative diseases such as Parkinson's and Alzheimer's disorders. Stem cell therapies offer several benefits over the conventional therapeutic methods that raise its preference for curing degenerative diseases. Recently developed stem cell therapies generate healthy cells by replacing the defective cells through minimally invasive techniques. Therefore, the geriatric population relies on stem cell therapies that provebeneficial for industry growth.

About Us:

Market Study Report LLC allows companies to manage and control all corporate research purchases to consolidate billing and vendor management. Eliminate duplicate purchases and customize content and license management.

Contact Us:

Market Study Report LLC 4 North Main Street, Selbyville, Delaware 19975 USA Phone:1-302-273-0910 US Toll-Free:1-866-764-2150 Email: sales@marketstudyreport.com Website: https://www.marketstudyreport.com Blog: https://www.marketstudyreport.com/blog/

Related Links Stem Cell Therapy Market will exceed USD 15 billion by 2025Cell Banking Outsourcing Market 2019-2025

Press Release Service by Newswire.com

Original Source: Cell Culture Market Size to Exceed US $42 Billion by 2026

Read the original:
Cell Culture Market Size to Exceed US $42 Billion by 2026 - Post Register